

News Release

Suven Revenue up by 6%; PAT down by 5% for the year ended March 2019

HYDERABAD, INDIA (25 May' 2019) – Suven Life Sciences Limited, a biopharmaceutical company specialized in CRAMS for global life science companies and drug discovery and developmental activities in Central Nervous System disorders, today announced its audited financial results for the quarter and year ended 31st March 2019. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 25th May' 2019 at Hyderabad.

Financial Highlights for the 4th Quarter ended March' 2019 (QoQ):

Growth in income	INR 2571 Mn vs 1348 Mn - up by 91%
Growth in PAT	INR 680 Mn vs 252 Mn - up by 170%
Growth in EBIDTA	INR 1090 Mn vs 414 Mn – up by 164%

Financial Highlights for the year ended March' 2019:

Growth in income	INR 6877 Mn vs 6485 Mn - up by 6%
Growth in PAT	INR 1499 Mn vs 1582 Mn - down by 5%
Growth in EBIDTA	INR 2478 Mn vs 2562 Mn - down by 3%

Suven's expenses on innovative R&D in Drug Discovery stood at INR 602 Mn (previous year INR 585 Mn) constituting 9% on revenue for the year ended Mar' 2019.

On consolidation of the accounts of Suven Neurosciences, Inc., USA, the wholly owned subsidiary, the PAT reduced to INR 868 Mn (previous year INR 1234 Mn) and expenditure on R&D increased to INR 1199 Mn (previous year INR 902 Mn).

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited